Symbols

BSX

Boston Scientific·NYSE

--(--)

BSX fundamentals

BSX Q4 2025 Earnings

Boston Scientific (BSX) released its earnings on Feb 4, 2026: revenue was 5.29B (YoY +15.90%), beat estimates; EPS was 0.8 (YoY +14.29%), beat estimates.

Revenue / YoY

5.29B

+15.90%

EPS / YoY

0.8

+14.29%

Report date

Feb 4, 2026

BSX Earnings Call Summary for Q4,2025

Q4 2025 Beat: 14.3% operational revenue growth, $0.80 EPS (+15%), and $3.659B free cash flow.
EP Dominance: 35% Q4 EP growth, 70% U.S. PFA penetration, and 29% WATCHMAN growth.
2026 Outlook: 10-11% organic growth, 12-14% EPS growth, and $4.2B free cash flow.
Strategic Moves: Penumbra acquisition (Q2 2026), Siemens 4D ICE partnership, and CHAMPION trial potential for 20M patient expansion.

Earnings

EPS

Revenue

Revenue & Expenses

BSX has released its 2025 Q4 earnings report, with revenue of 5.29B, reflecting a YoY change of 15.90%, and net profit of 670.00M, showing a YoY change of 19.22%. The Sankey diagram below clearly presents BSX's revenue sources and cost distribution.

Key Indicators

Boston Scientific (BSX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Boston Scientific (BSX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Boston Scientific (BSX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Boston Scientific (BSX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown